PAGBAM advises APx Acquisition Corp. I on the signing of a business combination agreement signed together with OmnigenicsAI Corp and MultiplAI Health Ltd for the creation of a global AI-based genomics platform.
APx Acquisition Corp. I (“APx”), OmnigenicsAI Corp (“OmigenicsAI”) and MultiplAI Health Ltd (“MultiplAI”) entered into a business combination agreement (the “BCA”).
APx is a publicly traded special-purpose acquisition company while OmigenincsAI is a precision medicine company incubated by Bioceres Group and MultiplAI a AI-based preventive medicine company based in the United Kingdom.
The BCA led to the creation of a global genomics company, whose shares will be publicly traded and will use artificial intelligence (AI) to advance the field of precision medicine.
Greenberg Traurig, LLP, Maples & Calder (Cayman) LLP and Pérez Alati, Grondona, Benites & Arntsen (“PAGBAM”) acted as legal advisors to APx. Linklaters LLP, Ogier and Marval, O'Farrell & Mairal, as legal advisors to OmnigenicsAI.
PAGBAM acted as Argentinean legal counsel to APx led by the corporate team, formed by partner P. Eugenio Aramburu and associates Nicolás del Campo Wilson and Azul María Juárez Pereyra, supported by the antitrust team comprised of the partner Luis D. Barry and counselor M. Clara Rodríguez Llanos and of data privacy issues by the counselor Pia Politi.
